The commercial real estate finance sector presents a fascinating dichotomy for Walker & Dunlop. While the company continues to announce billion-dollar transactions, its stock price tells a more complex and contradictory story, navigating a clear downward trend despite strong operational performance.
Impressive Transaction Volume Amid Market Shifts
Demonstrating its significant role in commercial property financing, Walker & Dunlop recently structured over $1 billion in refinancing for a portfolio of nine multifamily properties across California and Hawaii. This substantial deal, executed through the Fannie Mae DUS® program, encompasses 3,099 residential units for the firm’s longstanding client, Douglas Emmett.
In a separate strategic move, the company originated more than $68 million in HUD loans for seven healthcare facilities located in Illinois and Wisconsin. This initiative provided clients with the crucial ability to convert short-term variable-rate debt into long-term fixed-rate financing, representing a sophisticated approach to risk management during a period of economic uncertainty.
Share Price Performance Tells a Different Story
Despite these operational successes, Walker & Dunlop’s equity performance has faced significant headwinds. The stock declined 1.53% in a recent session, closing at $86.26. Year-to-date performance shows a decline of nearly 10%, which extends to a 14% drop when measured over the past twelve months.
A potential silver lining emerges when examining the quarterly performance, with shares gaining over 20% during the latest three-month period. However, technical indicators suggest continued fragility. The stock generated a sell signal from a pivot top point on September 5, followed by an additional bearish signal from the 3-month MACD indicator on the same date. Technical support levels are currently identified at $79.91 and $70.53.
Should investors sell immediately? Or is it worth buying Walker, Dunlop?
Analyst Sentiment: Cautiously Optimistic
Wall Street analysts maintain a generally positive outlook, with a consensus rating between “Buy” and “Moderate Buy” and an average price target of $92.50. However, a note of caution has emerged recently. While maintaining an “Outperform” rating on April 17, Keefe, Bruyette & Woods reduced their price target from $105 to $95.
The company’s second-quarter earnings provide substantial evidence for optimism. Walker & Dunlop reported EPS of $1.15, significantly surpassing expectations of $0.74 by 55.41%. Revenue climbed to $319.24 million, exceeding forecasts of $275.84 million and representing a 17.9% year-over-year increase.
Segment performance revealed particularly strong results in the Capital Markets division, which recorded diluted EPS of $0.97—a dramatic 194% improvement compared to the same quarter last year. Only the Servicing and Asset Management division showed a slight decrease, reporting $1.10 per share versus $1.19 in the second quarter of 2024.
Looking forward, management anticipates EPS growth of 6.44% to $5.29 per share for the coming year. This projection is supported by ambitious operational targets, including $600 million in Tax Credit Equity and over $1 billion in deployment through their investment platform during the second half of the year.
The central question for investors remains whether these fundamental strengths can ultimately overcome the prevailing technical downward pressure on the stock price.
Ad
Walker, Dunlop Stock: Buy or Sell?! New Walker, Dunlop Analysis from January 27 delivers the answer:
The latest Walker, Dunlop figures speak for themselves: Urgent action needed for Walker, Dunlop investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 27.
Walker, Dunlop: Buy or sell? Read more here...
